1084 related articles for article (PubMed ID: 27299311)
1. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date.
Bobo D; Robinson KJ; Islam J; Thurecht KJ; Corrie SR
Pharm Res; 2016 Oct; 33(10):2373-87. PubMed ID: 27299311
[TBL] [Abstract][Full Text] [Related]
2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
3. Cancer nanotherapeutics in clinical trials.
Lytton-Jean AK; Kauffman KJ; Kaczmarek JC; Langer R
Cancer Treat Res; 2015; 166():293-322. PubMed ID: 25895874
[TBL] [Abstract][Full Text] [Related]
4. Nanomedicines and nanodiagnostics come of age.
Uchegbu IF; Siew A
J Pharm Sci; 2013 Feb; 102(2):305-10. PubMed ID: 23175462
[TBL] [Abstract][Full Text] [Related]
5. Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
He H; Liu L; Morin EE; Liu M; Schwendeman A
Acc Chem Res; 2019 Sep; 52(9):2445-2461. PubMed ID: 31424909
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study.
Eifler AC; Thaxton CS
Methods Mol Biol; 2011; 726():325-38. PubMed ID: 21424459
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicines: From Bench to Bedside and Beyond.
Havel H; Finch G; Strode P; Wolfgang M; Zale S; Bobe I; Youssoufian H; Peterson M; Liu M
AAPS J; 2016 Nov; 18(6):1373-1378. PubMed ID: 27480318
[TBL] [Abstract][Full Text] [Related]
8. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
[TBL] [Abstract][Full Text] [Related]
9. Challenges in development of nanoparticle-based therapeutics.
Desai N
AAPS J; 2012 Jun; 14(2):282-95. PubMed ID: 22407288
[TBL] [Abstract][Full Text] [Related]
10. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.
Yang J; Wang X; Wang B; Park K; Wooley K; Zhang S
Adv Drug Deliv Rev; 2022 Nov; 190():114525. PubMed ID: 36100142
[TBL] [Abstract][Full Text] [Related]
11. Safety of Nanoparticles in Medicine.
Wolfram J; Zhu M; Yang Y; Shen J; Gentile E; Paolino D; Fresta M; Nie G; Chen C; Shen H; Ferrari M; Zhao Y
Curr Drug Targets; 2015; 16(14):1671-81. PubMed ID: 26601723
[TBL] [Abstract][Full Text] [Related]
12. What nanomedicine in the clinic right now really forms nanoparticles?
Svenson S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2014; 6(2):125-35. PubMed ID: 24415653
[TBL] [Abstract][Full Text] [Related]
13. Nanopharmaceuticals (part 2): products in the pipeline.
Weissig V; Guzman-Villanueva D
Int J Nanomedicine; 2015; 10():1245-57. PubMed ID: 25709446
[TBL] [Abstract][Full Text] [Related]
14. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines.
Dawidczyk CM; Kim C; Park JH; Russell LM; Lee KH; Pomper MG; Searson PC
J Control Release; 2014 Aug; 187():133-44. PubMed ID: 24874289
[TBL] [Abstract][Full Text] [Related]
15. Regulatory aspects on nanomedicines.
Sainz V; Conniot J; Matos AI; Peres C; Zupancic E; Moura L; Silva LC; Florindo HF; Gaspar RS
Biochem Biophys Res Commun; 2015 Dec; 468(3):504-10. PubMed ID: 26260323
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures.
Ragelle H; Danhier F; Préat V; Langer R; Anderson DG
Expert Opin Drug Deliv; 2017 Jul; 14(7):851-864. PubMed ID: 27730820
[TBL] [Abstract][Full Text] [Related]
17. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives.
Foulkes R; Man E; Thind J; Yeung S; Joy A; Hoskins C
Biomater Sci; 2020 Sep; 8(17):4653-4664. PubMed ID: 32672255
[TBL] [Abstract][Full Text] [Related]
18. Updated Regulatory Considerations for Nanomedicines.
Subin TS; Vijayan V; Kumar KJR
Pharm Nanotechnol; 2017; 5(3):180-191. PubMed ID: 28641516
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of nanomedicines for prostate cancer: An update.
Lakshmanan VK
Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723
[TBL] [Abstract][Full Text] [Related]
20. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
Moore TJ; Furberg CD
JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
